{"id":"NCT00566722","sponsor":"Abbott","briefTitle":"Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy","officialTitle":"Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2009-04","completion":"2009-04","firstPosted":"2007-12-04","resultsPosted":"2010-05-28","lastUpdate":"2011-04-12"},"enrollment":152,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"Open Label","type":"EXPERIMENTAL"}],"summary":"The objective of this study was to evaluate the safety and efficacy profile of Humira (adalimumab) in patients who had a sub-optimal response to prior systemic therapy. This open-label study was conducted in a patient population of moderate to severe chronic plaque psoriasis patients, which is an approved patient population for adalimumab.","primaryOutcome":{"measure":"Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Sub-optimal Response to MTX","deltaMin":25,"sd":null},{"arm":"Sub-optimal Response to Narrow-band Ultraviolet-B","deltaMin":14,"sd":null},{"arm":"Sub-optimal Response to Etanercept","deltaMin":40,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":25,"countries":["United States","Canada"]},"refs":{"pmids":["21414495"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":["Upper respiratory tract infection","Fatigue","Nasopharyngitis","Injection site erythema","Headache"]}}